申请人:ZAFGEN INC
公开号:WO2019118612A1
公开(公告)日:2019-06-20
The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
该披露提供了至少部分针对肝脏、肠道和/或肾脏的化合物,以及它们在治疗肝脏、肠道和/或肾脏疾病中的用途,如非酒精性脂肪肝、酒精性脂肪肝、肝细胞癌、肝硬化和乙型肝炎;和/或慢性肾脏疾病、肾小球疾病,如IgA肾病、狼疮性肾炎或多囊肾病。这些化合物被认为对甲硫氨酰氨肽酶2具有活性。